This article explains why a N-Assay for the coronavirus is

New Post Public Reply Private Reply Replies (1) Message Board
nmbr1stckpckr
440
This article explains why a N-Assay for the coronavirus is critically needed!

https://www.nbcnews.com/health/health-care/ma...g-n1156006

"Several versions of a test are in use in the U.S., including the one developed by the Centers for Disease Control and Prevention. The CDC has made its test available to qualified laboratories, but some private labs lack the equipment to run it, Birenbaum said."

This is likely in reference to the machines needed to do PCR. N-Assay would be cheap!

"In the past week, Quest and LabCorp — two of the country's biggest clinical testing providers — began rolling out their own commercial tests to doctors and medical providers. But results typically take three to four days from the time specimens are picked up, the companies said."

Three to four days?! Probably because they have to ship the sample to the lab with PCR machines and then get put queue to process along with all the other samples. I recall that PCR machines require a qualified technician to operate. N-Assay is a point of care test.

"The turnaround is usually far quicker for smaller private labs and academic labs, because the testing is conducted on site instead of shipped to a central facility. Several private labs said they would be able to produce results within four hours once they were cleared to begin testing.

Quick turnaround is critical to slowing the virus, as an infected person may expose others before getting results back."


Three to four hours if the equipment is available onsite. I wonder how this duration is impacted by volume of test requested. They would have to be able to scale up with the number of PCR machines, but keep in mind that these machines are $$$$$. I think time to result was measured in minutes for the N-Assay.

"So far, the FDA has received requests from 14 private labs for expedited authorization, and 10 of them have begun patient testing, according to a spokesperson for the FDA. Many more labs and diagnostic device companies haven't even gotten to the point of requesting authorization because they are still developing their tests and trying to meet the FDA's requirements, industry representatives and lab experts said.

"We are talking to them around the clock, and our door is open for any developers who want to have a test for use in the U.S.," FDA Commissioner Stephen Hahn said Saturday."


If well-funded labs are having this much difficulty with a receptive CDC, I wonder what chance our little Company has. At least there would be minimal development time since all the ingredients are available and its only a matter of configuring the N-Assay to detect antibodies of the coronavirus.

"The University of Vermont Medical Center hasn't developed a test in-house and doesn't have the equipment to run the CDC's test. So it is waiting for commercial manufacturers to develop a test that its lab can use, Wojewoda said. And getting the test isn't the end of the process. "When we get it into the lab, we need to make sure it works in our hands," she said, noting that the validation process could take another week to complete.

One of the diagnostic tests the FDA is reviewing is made by Thermo Fisher, a major testing manufacturer. It would cut processing time to four hours, said Ron O'Brien, a spokesman for the company. However, FDA approval could still take weeks, O'Brien said."


Public labs are under pressure waiting for the CDC to get their act together and are open to using tests developed by private companies. And even the test from Thermo Fisher cuts processing time to four hours -- PCR? And I wonder why he didn't use the words "provide results" instead of "cut processing time"? Makes me think additional time is needed for the result.

"We've had a lot of issues with payments not covering the cost of the tests," Birenbaum said. "For our labs, it's a big investment to gear up for this. We're going to need to know if it's at least going to cover costs."

A lot of the cost is the investment in the PCR machines! Reimbursements to the labs in the thousands? Remember that guy who paid $3,000.00 to get himself tested? The N-Assay would be in the hundreds!!

"An academic research institute in New Jersey spent weeks developing a test that it says will produce results within four hours. Hackensack Meridian Health said in a statement that the in-house test will drastically reduce its turnaround time, as it consults with the state Health Department and then sends results to a state lab, which can take one to two days."

That "four hours" again....

It's a no brainer!!! All we need is for the CDC to give us a shot, but it sounds like they are only considering fully developed kits , which requires money that the Company does not have. All its resources are tied up with the goal of commercial launch of N-Assay for a handful of bacteria mentioned in previous updates.

This situation makes me sick.

On the other hand, I listened to some expert on pandemics say that the coronavirus will eventually turn into another seasonal flu. I didn't know, but the flues that go around now were also pandemics when they first came about. The goal now is to make it so that not everyone gets sick all at once such that it overwhelms our healthcare system.
1

Nanologix Inc (NNLX) Stock Research Links

NNLX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 81

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 178

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 135

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
AI Echo Study Sharpens a Difficult HFpEF Diagnosis

Updated Category News Views 88

A single echo clip may be doing more useful work than plenty of flashy healthcare AI demos. The November 2026 Journal of Cardiac Failure focus issue puts a hard number on that possibility: pairing an AI read of a routine echocardiogram clip with the H?FPEF clinical score identified 78% of patients with hemodynamically confirmed HFpEF, versus 48% with the score alone. That...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 95

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 189

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 196

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading

Top 5 Most Recently Viewed Articles

Orion180 Unveils Innovative Customizable Flood Insurance

Updated Category News Views 177

Orion180 Launches Customizable Residential Flood Insurance Orion180 is making waves in the insurance sector by introducing its latest offering: a Residential Private Flood Insurance product designed to meet a variety of homeowner needs. Based in Melbourne, this innovative insurance leader is set to change how we approach flood insurance with a product that emphasizes...

Continue Reading
DIFD AUTO Revolutionizes Global Car Buying with Crypto Payments

Updated Category News Views 306

Transforming the Car Buying Experience with Cryptocurrency Today, as the digital landscape continues to evolve, DIFD AUTO stands at the forefront of a revolutionary shift in how consumers purchase vehicles. As a leading platform for cryptocurrency-based car transactions, DIFD AUTO allows customers around the globe to purchase brand-new, certified cars using major...

Continue Reading
Curtiss-Wright Reports Impressive Q3 Results and Outlook Boost

Updated Category News Views 102

Curtiss-Wright's Positive Financial Performance Curtiss-Wright Corporation (NYSE: CW) is a well-known global company recognized for providing highly engineered products and services. Recently, the company reported noteworthy financial results for the third quarter. The sales surged nearly 10% year-over-year, coming close to $800 million, with exceptional growth especially...

Continue Reading
Darling Ingredients Reports Q3 2024 Results Amid Challenges

Updated Category News Views 312

Third Quarter 2024 Overview Darling Ingredients Inc. today reported net income of $16.9 million, or $0.11 per diluted share for the third quarter of 2024. This represents a significant decline compared to net income of $125.0 million, or $0.77 per diluted share, in the third quarter of 2023. The notable decrease in net income is attributed to lower fat prices and reduced...

Continue Reading
Investigation Launched for Investors of Spyre Therapeutics, Inc.

Updated Category News Views 127

Investigation Launched into Spyre Therapeutics, Inc. Pomerantz LLP has announced an investigation on behalf of investors of Spyre Therapeutics, Inc., known by its stock ticker, NASDAQ: SYRE. This inquiry stems from allegations that the company, along with some of its executives and board members, may have been involved in securities fraud or engaged in other unlawful...

Continue Reading